In the advanced disease study, the proportion of patients with detectable IL1β was significantly higher in gastro-oesophageal junction cancers than in other sites (p = 0.006) and IL12 was detected more frequently in gastric cancers, although this was borderline significant (p = 0.051). Here, IL1B is linked to gastric cancer.